key: cord-0730900-y3aeyohi
authors: Chhetri, Abhijit; Chettri, Sailesh; Rai, Pranesh; Sinha, Biswajit; Brahman, Dhiraj
title: Exploration of Inhibitory Action of Azo imidazole Derivatives against COVID-19 Main Protease (M(pro)): A Computational Study
date: 2020-08-31
journal: J Mol Struct
DOI: 10.1016/j.molstruc.2020.129178
sha: 40b7be516d471223cdb568cc0911f533beeb686e
doc_id: 730900
cord_uid: y3aeyohi

Four novel ionic liquid tagged azo-azomethine derivatives (L1-L4) have been prepared by the condensation reaction of azo-coupled ortho-vaniline precursor with amino functionalised imidazole derivative and the synthesized derivatives (L1-L4) have been characterized by different analytical and spectroscopic techniques. Molecular docking studies were carried out to ascertain the inhibitory action of studied ligands (L1-L4) against the Main Protease (6LU7) of novel coronavisrus (COVID-19). The result of the docking of L1-L4 showed a significant inhibitory action against the Main protease (M(pro)) of SARS-CoV-2 and the binding energy (ΔG) values of the ligands (L1-L4) against the protein 6LU7 have found to be −7.7 Kcal/mole (L1), −7.0 Kcal/mole (L2), −7.9 Kcal/mole (L3), and −7.9 Kcal/mole (L4).The efficiency of the ligands has been compared with the FDA approved and clinically trial drugs such as remdesivir, Chloroquin and Hydroxychloroquin and native ligand ligand N3 of main protease 6LU7 to ascertain the inhibitory potential of the studied ligands (L1-L4) against the protein 6LU7. Pharmacokinetic properties (ADME) of the ligands (L1-L4) have also been studied.

After the outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in December 2019 from the Wuhan city of China, the infectious disease was declared pandemic by World Health Organization (WHO) on 11the March 2020 and subsequently, the whole world witnessed a global health emergency [1] . As of June 11 th 2020, the COVID-19 disease has spread to the whole world with over 7.4 million confirmed cases and over 0.4 million confirmed deaths (worldometer, June 11 th 2020). After the declaration of novel coronavirus infection as pandemic, a number of countries took a preventive measure to slow down the spread of the coronavirus (COVID-19) by implementing mandatory lockdown or national quarantine and as a result of mandatory home quarantine or isolations, more than a third of the planet's population faced some form of restriction (Business Insider, April 17 th 2020). Early research on COVID-19 have shown that the cross species and human to human transmission of the virus is regulated by spike protein receptor binding domain and its host receptor (ACE2) as similar to SARS-CoV which was outbreak in 2002 [2] . Till date, no specific vaccine or therapeutic agents are available for the treatment of COVID-19 infection and several existing FDA approved antmaliarial and antiviral drugs have been formulated as a supportive care for the treatment of this infection [3] . Therefore, a rapid formulation of novel compounds as a potentential therapeutic agent for COVID-19 infection is an important mission [4] . Recent studies on SARS-CoV-2 have shown that the 3CL hydrolase (chymotrypsin-like protease, PDB ID: 6LU7), also known as the main protease (Mpro) of novel coronavirus (SARS-CoV-2) plays an important role in the life cycle of coronavirus and thus, its inhibition could provide a promising therapeutic principle for developing strategic and specific treatment against COVID-19 infection [5] [6] . Apart from the existing FDA approved antiviral and antimalarial drugs, Traditional Chinese Medicine has gained a lot of interest to treat coronavirus infection in China [7] [8] [9] [10] [11] [12] . Identification of potential inhibitors for specific disease by traditional methods are time consuming and expensive.

However, in-silico techniques such as molecular docking and molecular dynamic have gained lot of interest for the identification of potential inhibitors for specific disease in recent years [13] [14] . Since, the main protease (3CL pro ) of coronaviruses is conserved and therefore many research groups are engaged in finding the effective inhibitors for COVID-19 Protease (Mpro) by virtual screening approach using the library of small molecules ( antiviral, antimalarial, plant derived, fungal metabolites and synthesized molecules) [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] . Recently, computer aided drug design namely molecular docking and molecular dynamic study have gained a lot of interest in the field of drug designing for the treatment of specific disease [32] [33] . On the other hand, azo or diazene compounds containing conjugated chromophoric azo (-N=N-) group are an important class of organic colorants which are mostly studied during recent years [34] . These colorant compounds are widely used as a class of dyes due to their versatile application in various fields such as the dyeing of textile fiber, coloring of different materials, plastics, cosmetics industries, biological-medical studies and advanced application in organic synthesis [35] [36] . Furthermore, the azo compounds were found to possess a variety of biological activities such as antibacterial, antifungal, antiviral and antiinflammatory etc, [37] [38] [39] [40] . Interestingly, azo compounds are found to involve in many biological processes such as nitrogen fixation, inhibition of DNA, RNA and protein synthesis, and carcinogenesis [41] . Moreover, Microorganisms, fungi, fungal endophytes, lichenized, ascomycetes, plant parts (bark, berries, leaves, roots, and wood), and marine invertebrates are found to posses natural diazine or azo alkaloids. In recent years, several azo metabolites have been isolated from actenomycetes, fungal species, terrestrial and marine sources [42] . Valanimycin and its derivatives (isloalted from Streptomyces viridifaciens, MG456-hF10), maniwamycins A and B (isolated from Streptomyces prasinopilosus), azoxybacilin (isolated from Bacillus cereus, NR2991), Elaiomycin (isolated from Streptomyces hepaticus), Elaiomycins K, L and amide elaiomycin K (isolated from Streptomyces sp., Tu¨ 6399), jietacins A and B (isolated from Streptomyces sp.), lyophyllin (isolated from mushroom Lyophyllum shimeji), calvatic acid (isolated from fungi Calvatia craniformis) etc, are the actenomycetes and fungal metabolites which have naturally occurring azo groups and they are found to posses antibiotic activities [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] . Thus, it was thought worthwhile to investigate the inhibitory potential of the synthesized azo derivatives against the main protease of COVID-19 and therefore, in this article, we report the computational study on inhibitory action of synthesized Azo imidazole derivatives (L1-L4) against COVID-19 main Protease (M pro ).

All the reagents used were of analytical grade and used without further purification. orthovaniline, Aniline, 2 chloroaninline, 4-chloroaniline, and 4-fluoro aniline were procured from Sd fine chemical company, India.1-methylimidazole, KPF 6 and 2bromoethylaminehydrobromide were procured from sigma Aldrich and used without further purification. All the solvents used were of spectroscopic grade.

The IR spectra of the synthesized compounds were analyzed using Perkin-Elmer Spectrum FT-IR spectrometer (RX-1) operating in the region 4000 to 400 cm -1 in KBr. 1 H-NMR spectra were recorded at room temperature on a FT-NMR (Bruker Advance-II 400 MHz) spectrometer using DMSO-d 6 as solvents and chemical shifts are quoted in ppm downfield of internal standard tetramethylsilane (TMS). Elemental microanalyses (C, H and N) were conducted by using Perkin-Elmer (Model 240C) analyzer. The purity of the prepared compounds was confirmed by thin layer chromatography (TLC) on silica gel plates and the plates were visualized with UV-light and iodine as and when required.

The X-ray crystallographic structures of main protease (Mpor, PDB ID 6LU7) of SARS-CoV-2 has been retrieved from the Protein Data Bank (PDB) (http: //www.pdb.org.) database. Graphical User Interface program -Auto Dock Tools (ADT) 1.5.6‖ from Molecular Graphics Laboratory (MGL) developed by Scripps Research Institute has been employed for the preparation of protein for docking study [53] . Input file of receptor protein for the docking study is created by taking specific china (Chain A) of the protein (6LU7). In a typical receptor protein preparation, water molecules and hetero atoms along with the cocrystallised ligands in PDB crystal structures were removed and subsequently, the receptor .pdbqt file has been created by adding polar hydrogen atoms and Kollman united atom charges [54] . The three dimensional (3D) structures of ligands (L1-L4) were drawn using Chemsketch (ACD/Structure Elucidator, version 12.01, Advanced Chemistry Development, Inc., Toronto, Canada, 2014, http://www.acdlabs .com.) and geometry optimization of the ligands (L1-L4) were carried out using MM2 program incorporated in Chem. Draw Ultra 8.0 and further optimization of geometry of each molecule were carried out with the MOPAC 6 package using the semi-empirical AM1 Hamiltonian [55] . The input .pdbqt file of the ligands was generated using Auto Dock Tools (ADT). As the ligand molecules (L1-L4) are non peptides, therefore, Gasteiger charge was assigned and then non-polar hydrogen was merged.

The structure of the ligands L1-L4 is given in Fig.1 . 

The analytical and spectroscopic data for each of the synthesized azo imidazole derivatives (L1-L4) are given in supplementary data file SD1.

Azo imidazole derivatives has been successfully prepared by the condensation reaction of 1- were found to be air stable solid, soluble in common organic solvents like methanol, ethanol, acetonitrile, DMF, DMSO etc., and intensely colored compounds.

In order to ascertain the binding mode in the synthesized azo imidazole derivatives L1-L4, the IR spectra of the compounds were closely analyzed. In the solid state IR spectrum of the Azo imidazole derivatives (L1-L4), appearance of bands in the IR spectra of L1-L4 in the range 1620-1647 cm -1 can be assigned to the stretching vibration of azomethine linkage ν(-C=N) [64, 66] . Astrong band at 33100-3436 cm -1 can be assigned to stretching frequency of OH group, ν(OH) group [67] . A band appearing in the range 1593-1616 cm-1 in the IR spectra of L1-L4 derivatives can be assigned to ν(C=C) stretching frequency. Also, the N=N stretching frequency of the synthesized compounds are found at 1542-1552 cm -1 and 1453-1500 cm -1 and the N=N bending vibrations are found in the range 1153-1176 cm -1 and 956-969 cm -1 . IR spectra of the representative compound L1 is depicted in Fig.2 . A band in the range 838-842 cm -1 in the IR spectrum of derivatives (L1-L4) can be assigned for stretching vibration of PF 6 group [65] . Thus the IR spectral data therefore supports the formation of the compounds (L1-L4). The IR spectra of L2, L3 and L4 are depicted in supplementary figures ( Fig. S1.1-Fig. S1 .3). Lipophilicity is an important phartmacokinetic property of drug candidate in the development of its dosage form, because drug molecules must pass through the lipid bilayer of most cellular membranes. Therefore, generally it is believed that for a drug molecule to have good absorption, it must be lipophilic. According to Lipinski's Rule of Five, the partition coefficient should be positive, but less than 5 i.e., log 10 PC=5 [71] . Therefore, the studied violations and these compounds can serves as a potential drug candidate.

Recent study on structural analysis of M pro of SARS-CoV-2 have shown that it also has same location of active site as Mpro of SARS virus and it is located between the domain I and domain II of protein 6LU7 (Fig. 4) . are highly bioactive and some of them have been used as antibiotics to cure specific disease [43] [44] [45] . Prontosil and Phenazopyridine are FDA approved antibiotic drugs containg Azo group.Prontosil is widely used antibacterial drug which contains azo linkage and sulfonamide group and it has also been used to cure puerperal fever [78] [79] . Phenazopyridine is used as local analgesic effects on the urinary tract infection and also sometimes used with antibiotics for immediate symptomatic relief [80] . Since, the traditional method of drug formulation is time consuming and therefore, computational method such as molecular docking and molecular dynamic simulation study may be an alternative way to find out the potential drug candidates for the specific disease at relatively less time [81] . Van der walls

It has been reported that the amino acid residues His41, Cyd145 and Glu166 are important residues in substrate binding site and involvement of these residues in the formation of hydrogen bond could be prominent for the inhibitory effect of main protease (M pro ) [82] . The docking result of L1 with the Protease (6LU7) showed that the ligand (L1) fits inside the core pocket region of the protease at the interface between domain I and domain II (Fig. 5) . between the π-electron of ligand L3 and S atom of amino acid residue (Fig. S1.7) . The other types of interactions are π-alkyl (π electron of His163 and His172 with OCH 3 group) and πdonor hydrogen bonds (Thr24, Thr25, Thr26, Phe140 and Cys145). Apart from these interactions, the residues Leu27, His41, Thr45, Met49, Asn142, Glu166, Gln189 and Thr190 are found to interact with L3 through Van der walls interactions. An unfavorable acceptoracceptor interaction between the ligand and residue Leu141 has also been observed. respectively. Thus from this comparison, it may be conclude that the ligands (L1-L4) could act as a potential inhibitor molecule against SARC-CoV-2.

In this article, we have reported the molecular docking study of four ligands (L1-L4) against the main protease (6LU7) of SARS-CoV-2 to ascertain the inhibitory potential of these ligands. The docking results attributed various types of protein-ligand interactions and it is also seen that the lignads shows significant interactions at the interface between domain I and domain II. Furthermore, most of the ligands show interaction at the Cys-His catalytic dyad.

The pharmacokinetic study has revealed that the ligands (L1-L4) could act as a potential drug candidate. Thus, it is evident that various kind of favorable interactions exist between the ligands (L1-L4) and the main protease 6LU7. Therefore, on the basis of computational study, it may concluded that the ligands (L1-L4) could act as potential inhibitor against the main protease (6LU7) of SARS-CoV-2.Furthermore, in vivo and in vitro study is required to ascertain the proper binding mechanism and understanding the drug behavior of the studied ligands (L1-L4)

The authors do not have any conflict of interest.

I wish to submit an original research article entitled "Exploration of Inhibitory Action of Azo imidazole Derivatives against COVID-19 Main Protease (M pro ): A Computational Study" by Abhijit Chhetri, Sailesh Chettri, Biswajit Sinha, Pranesh Rai and Dhiraj Brahman to be considered for publication in your reputed journal.

In this research work, we synthesized some azo imidazole derivatives (L1-L4) and an attempt has been made to investigate the inhibitory potential of synthesized derivatives against the main protease (M pro , 6LU7) of SARS-CoV-2 through molecular docking study. The docking results have been compared with the previously reported docking report of FDA approved and clinically trial drugs such as Remdsivir, Chloroquin and Hydroxychlkoroquin and the native ligand N3 of protein 6LU7. The result of the docking of L1-L4 showed a significant inhibitory action against the Main protease (M pro ) of SARS-CoV-2 and the binding energy values of the ligands (L1-L4) against the protein 6LU7 have been found to be -7.7 Kcal/mole (L1), -7.0 Kcal/mole (L2), -7.9 Kcal/mole (L3) and 7.9 Kcal/mole (L4) with predicted inhibitory constant (pK i ) 1.72µM, 5.76µM, 1.22µM and 1.22µM respectively.Thus, it is evident from the docking result that the ligands (L1-L4) could act as potential inhibitors for protein 6LU7 of SARC-CoV-2. However, further in-vivo and in-vitro studies are required to understand the mechanism of these ligands as inhibitors against protein 6LU7 of SARS-CoV-2.

Global spread of COVID-19 and pandemic potential

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia

Favipiravir: Structural Analysis and Activity against COVID-19

Structure of M pro from SARS-CoV-2 and discovery of its inhibitors

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective. Inter

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Traditional Chinese Medicine treatment of COVID-19

Traditional Chinese medicine for COVID-19 treatment

Traditional Chinese medicine is a resource for drug discovery against 2019 novel coronavirus (SARS-CoV-2)

Traditional Chinese Medicine: an effective treatment for 2019 novel coronavirus pneumonia (NCP). Chin

Computational screening of medicinal plant phytochemicals to discover potent pan-serotype inhibitors against dengue virus

Jensenone from eucalyptus essential oil as a potential inhibitor of COVID 19 corona virus infection

Molecular docking analysis of some phytochemicals on two sars-cov-2 targets

Anti-HIV drug repurposing against SARS-CoV-2

Anti-COVID-19 Effects of Ten Structurally Different Hydrolysable Tannins through Binding with the Catalytic-Closed Sites of COVID-19 Main Protease: An In-Silico Approach

The Molecular Docking Study of Potential Drug Candidates Showing Anti-COVID-19 Activity by Exploring of Therapeutic Targets of SARS-CoV-2

Molecular docking analysis of selected natural products from plants for inhibition of SARS-CoV-2 main protease

Identification of Potent Inhibitors of COVID-19

The potential chemical structure of anti-SARS-CoV-2RNA-dependent RNA polymerase

Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 protease against COVID-19

A Search for Medications to Treat COVID-19 via in Silico Molecular Docking Models of the SARS-CoV-2 Spike Glycoprotein and 3CL Protease

Molecular Docking Reveals the Potential of Aliskiren, Dipyridamole, Mopidamol, Rosuvastatin, Rolitetracycline and Metamizole to Inhibit COVID-19 Virus Main Protease

Peptide-like and small-molecule inhibitors against Covid-19

Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. Preprints

Virtual Screening based prediction of potential drugs for COVID-19

Candidate Drugs against SARS-CoV-2 and COVID-19

Identification of Dietary Molecules as Therapeutic Agents to Combat COVID-19 Using Molecular Docking Studies

Moroccan Medicinal plants as inhibitors against SARS-CoV-2 main protease: Computational investigations

Computer aided drug design: an overview

The synthesis, characterization, electrochemical character, catalytic and antimicrobial activity of novel, azo-containing Schiff bases and their metal complexes

Synthesis and absorption properties of some new azo-metal chelates and their ligands

Colour-constitution relationships in 2-acylamino-4-N,Ndiethylaminoazobenzene disperse dyes

Synthesis of 2-hydroxy-3-methoxy-5-(4-methoxyphenylazo) benzaldehyde. A new aldehyde for the preparation of biologically active molecules

Synthesis of diaryl-azo derivatives as potential antifungal agents

Heterocyclic compounds based on 3-(4-bromophenyl) azo-5-phenyl-2(3H)-furanone: anti-avian influenza virus (H5N1) activity

Antiviral and cytotoxic activities of aminoarylazo compounds and aryltriazene derivatives

Thermal stability study of some azo-derivatives and their complexes: Part 2. New azo-derivative pigments and their Cu (II) complexes

Pharmacological and Predicted Activities of Natural Azo Compounds

Isolation and properties of valanimycin, a new azoxy antibiotic

A novel valanimycin-resistance determinant (vlmF) from Streptomyces viridifaciens MG456-hF10

Novel Antifungal Antibiotics Maniwamycins A and B

Azoxybacilin, a Novel Antifungal Agent Produced by Bacillus Cereus NR2991

Isolation and Structure Elucidation

Elaiomycin, a new tuberculostatic antibiotic

isolation and chemical characterization

Jietacins A and B, new nematocidal antibiotics from a streptomyces sp

Structures of Jietacines: Unique α, β-unsaturated azoxy antibiotics

Synthesis and nematocidal activities of Jietacin A and its analogs

The mushroom ribosome-inactivating protein lyophyllin exerts deleterious effects on mouse embryonic development in vitro

A New Antibiotic, Calvatic Acid

The Scripps Research Institute

Molecular docking studies of some new imidazole derivatives for antimicrobial properties

Study on optimization of molecular structure using Hamiltonian algorithm

Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading

Pymol: An open-source molecular graphics tool

Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function

Ligand efficiency: a useful metric for lead selection

Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro

Synthesis, spectral properties, chemical descriptors and light harvesting studies of a new bioactive azo imidazole compound

-hydroxybenzylidene)-amino]-ethyl}-3-methyl-3H-imidazolium hexafluorophosphate

Synthesis, characterization and antibacterial studies of Mn(II) and Co(II) complexes of an ionic liquid tagged Schiff base

Synthesis of ionic liquid-supported Schiff bases

Physico-chemical characterization and biological studies of newly synthesized metal complexes of an Ionic liquid-supported Schiff base: 1-{2-[(2-hydroxy-5-bromobenzylidene) amino] ethyl}-3-ethylimidazolium tetrafluoroborate

Synthesis, characterization and microbiocidal studies of novel ionic liquid tagged Schiff bases

Chapter 31 -Physiological Aspects Determining the Pharmacokinetic Properties of Drugs. The Practice of Medicinal Chemistry

In silico drug metabolism and pharmacokinetic profiles of natural products from medicinal plants in the Congo basin

SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules

Chapter 11 -Oral Absorption Basics: Pathways, Physicochemical and Biological Factors Affecting Absorption. Developing Solid Oral Dosage Forms

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases

Structural elucidation of SARS-CoV-2 vital proteins: Computational methods reveal potential drug candidates against main protease, Nsp12 polymerase and Nsp13 helicase

Fused-ring structure of decahydroisoquinolin as a novel scaffold for SARS 3CL protease inhibitors

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease

Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

First Case of 2019 Novel Coronavirus in the United States

Chapter 3: Prontosil". The first miracle drugs: how the sulfa drugs transformed medicine

Oxford Handbook of Infectious Diseases and Microbiology

Role of Phenazopyridine in Urinary Tract Infections. Ind

Molecular Docking and Structure-Based Drug Design Strategies

Characterization of Trans-and Cis-Cleavage Activity of the SARS Coronavirus 3CLpro Protease: Basis for the in Vitro Screening of anti-SARS Drugs

Potential Candidate to Repurpose for Coronavirus Infection: Virtual Screening and Molecular Docking Study. Preprints

A search for medications to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2 spike glycoprotein and 3CL protease

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Molecular docking reveals the potential of Salvadora persica flavonoids to inhibit COVID-19 virus main protease

On Facing the SARS-CoV-2 (COVID-19) with Combination of Nanomaterials and Medicine: Possible Strategies and First Challenges

Potential Inhibitor of COVID-19 Main Protease (M pro ) From Several Medicinal Plant Compounds by Molecular Docking Study. Preprints

Graphical Abstract

The authors are grateful to the research facilities available at the Department of Chemistry,